Epigenetic modifiers such as HDAC inhibitors have thus been identified to promote sensitization of tumor cells to PD-1/PD-L1 immune checkpoint inhibitors via reversal of MDSC’s immunosuppressive effect on the cancer milieu, demonstrating synergistic effects with immunotherapeutic options in solid tumors (212). This evidence concerns the gene HDAC9 and cancer.